MARKET

CDXS

CDXS

Codexis Inc
NASDAQ
3.000
+0.060
+2.04%
After Hours: 3.000 0 0.00% 16:13 06/24 EDT
OPEN
2.960
PREV CLOSE
2.940
HIGH
3.030
LOW
2.920
VOLUME
277.20K
TURNOVER
0
52 WEEK HIGH
4.910
52 WEEK LOW
1.450
MARKET CAP
211.67M
P/E (TTM)
-3.1874
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CDXS last week (0617-0621)?
Weekly Report · 16h ago
Insider Returns Down To US$92k As Codexis' Stock Dips 18%
In the last year Codexis, Inc. Insiders bought US$156.4k worth of shares. The biggest insider purchase was by Stephen Dilly for US$101k in the past year. Codexis owns about 3.5% of the company. The company's share price has fallen 18% in the last week. You should look at the insider transactions at Codexis over the last 12 months.
Simply Wall St · 5d ago
Weekly Report: what happened at CDXS last week (0610-0614)?
Weekly Report · 06/17 09:18
Weekly Report: what happened at CDXS last week (0603-0607)?
Weekly Report · 06/10 09:18
Weekly Report: what happened at CDXS last week (0527-0531)?
Weekly Report · 06/03 09:19
CDXS, SMMT and OABI are among after hour movers
On the Move CDXS, SMMT and OABI are among after hour movers May 30, 2024. Zscaler, Ambarella and MongoDB are among the biggest gainers. MongoDB, on the move since 2008, is down 22% in the past year.
Seeking Alpha · 05/30 21:10
Codexis Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 05/30 13:03
Codexis Price Target Announced at $11.00/Share by Cantor Fitzgerald
Dow Jones · 05/30 13:03
More
About CDXS
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Webull offers Codexis Inc stock information, including NASDAQ: CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.